<DOC>
	<DOCNO>NCT02341781</DOCNO>
	<brief_summary>The objective study determine effectiveness lenalidomide subject relapse refractory Mantle Cell Lymphoma ( MCL ) follow ibrutinib treatment . MCL subject require treatment receive ibrutinib therapy consider population high unmet medical need . It therefore benefit data outcome treatment option available patient population . An observational study design choose collect clinical data already exist collect MCL subject treat lenalidomide . MCL subject receive lenalidomide either monotherapy combination treatment relapse progressed ibrutinib treatment refractory intolerant ibrutinib treatment eligible study . Lenalidomide need next subsequent treatment ibrutinib .</brief_summary>
	<brief_title>Observational Study Lenalidomide Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1 . Understand voluntarily sign informed consent document ( ICD ) , applicable , prior collection studyrelated data . 2 . Males females ≥ 18 year age time sign ICD ( informed consent applicable ) 3 . Diagnosis Mantle Cell Lymphoma ( MCL ) assess investigator . A copy pathology report establish diagnosis MCL must available 4 . Must receive least one dose ibrutinib must meet least one follow criterion : A. Relapse : Subjects relapse follow initial response CR ibrutinib ( ibrutinibcontaining regimen ) . Subjects may discontinue complete ibrutinib treatment time relapse , upper limit time last dose ibrutinib time relapse . B . Progressive disease ( PD ) : Subjects PD follow initial response PR ibrutinib ( ibrutinibcontaining regimen ) . Subjects may discontinue complete ibrutinib time progression , upper limit time last dose ibrutinib time progression . C. Refractoriness : Subjects . Best response stable disease ( SD ) treatment ibrutinib ( ibrutinibcontaining regimen ) , subsequently PD , ii . Best response PD anytime ibrutinib ( ibrutinibcontaining regimen ) D. Intolerance : Subjects require premature discontinuation ibrutinib reason PD prior plan end treatment . Potential reason premature discontinuation may include Adverse Event ( AE ) attribute ibrutinib inability continue ibrutinib reason . Subjects respond ibrutinib treatment must document PD/relapse follow discontinuation ibrutinib . The reason premature discontinuation ibrutinib record . exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>MANTLE CELL LYMPHOMA</keyword>
	<keyword>Multicenter</keyword>
	<keyword>Observational</keyword>
	<keyword>Lenalidomide ( Revlimid® )</keyword>
	<keyword>Relapsed progress</keyword>
	<keyword>Ibrutinib</keyword>
</DOC>